SCHEDULE: IAF, LLC Exits Significant Ernexa Stake

Sentiment:

Beneficial Ownership Update 18 August 2025 4:05 PM

📋All filings for Eterna Therapeutics INC

IAF, LLC has reduced its beneficial ownership in Ernexa Therapeutics Inc. to below 5%, triggering an exit filing.

Worse than expectedIAF, LLC has reduced its beneficial ownership in Ernexa Therapeutics Inc. to 4.1%, down from a previous stake above 5%, indicating a divestment of a significant portion of its holding.

Summary

IAF, LLC filed an Amendment No. 3 to its Schedule 13G for Ernexa Therapeutics Inc.
This filing serves as an 'exit filing' because IAF, LLC has ceased to be the beneficial owner of more than five percent of Ernexa Therapeutics Inc.'s outstanding common stock.
As of the event date of July 28, 2025, IAF, LLC beneficially owns 315,779 shares of Ernexa Therapeutics Inc. common stock.
This ownership represents 4.1% of the class, based on an aggregate of 7,670,889 shares of Common Stock outstanding as reported in Ernexa Therapeutics Inc.'s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025.

Sentiment

Score: 4

Explanation: The reduction of a significant institutional stake below the 5% threshold can be perceived negatively by the market, suggesting a lack of continued conviction or a strategic divestment by the investor. However, the filing itself is purely factual and does not provide reasons for the divestment.

Future Outlook

No forward-looking statements or guidance are provided in this beneficial ownership filing.

Industry Context

This filing reports a change in institutional ownership for Ernexa Therapeutics Inc., indicating a reduction in a significant stake by IAF, LLC. This type of event is common in the market as institutional investors adjust their portfolios based on their investment strategies and market outlook, but it does not inherently provide broader industry trends or competitive analysis.

Stakeholder Impact

Shareholders: May interpret the reduction in institutional ownership as a negative signal, potentially leading to selling pressure on the stock.

Key Dates

Date	Description
12/20/2023	Original Schedule 13G filed by IAF, LLC.
02/12/2025	Amendment No. 1 to Schedule 13G filed by IAF, LLC.
05/14/2025	Amendment No. 2 to Schedule 13G filed by IAF, LLC.
07/28/2025	Date of event which required the filing of this statement (IAF, LLC ceased to be a beneficial owner of more than five percent).
08/13/2025	Ernexa Therapeutics Inc. filed its Quarterly Report on Form 10-Q, reporting 7,670,889 shares of Common Stock outstanding.
08/18/2025	Signature date of this Amendment No. 3 to Schedule 13G.

Recommendation

hold

IAF, LLC's reduction of its stake below 5% is a notable event, as institutional divestment can signal a lack of conviction or a strategic shift. This could put downward pressure on the stock. However, without specific reasons for the divestment or updated financial performance from Ernexa Therapeutics Inc., a definitive 'sell' recommendation is premature. Investors should monitor future company announcements and financial reports to understand the broader context.

Keywords

Ernexa Therapeutics, IAF LLC, Schedule 13G, beneficial ownership, common stock, institutional investor, stake reduction

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.